See the original post:
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81%
Related Post
- RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership - April 24th, 2024
- T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024 - April 24th, 2024
- Eko2o S.A.S., a Majority-Controlled Subsidiary of MedCana/SFWJ Advances as Leading Infrastructure Supplier for Colombia’s Top Flower Producers - April 24th, 2024
- Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy - April 24th, 2024
- ImPact Biotech to Present Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at Upcoming Medical Conferences - April 24th, 2024
- Spectral AI Names Erich Spangenberg CEO of its IP Focused Subsidiary and Explores Potential Spin-Off of that Subsidiary - April 24th, 2024
- ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting - April 24th, 2024
- Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - April 24th, 2024
- Immunocore announces upcoming presentation and posters at ASCO 2024 - April 24th, 2024
- Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual... - April 24th, 2024
- Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - April 24th, 2024
- Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO - April 24th, 2024
- Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting - April 24th, 2024
- Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination... - April 24th, 2024
- BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in... - April 24th, 2024
- Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - April 24th, 2024
- BrightInsight Recognized Among Newsweek’s World’s Best Digital Health Companies 2024 List - April 24th, 2024
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - April 24th, 2024
- Virbac : Public release of Virbac Annual Report at 31 December 2023 (ESEF format) - April 24th, 2024
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of... - April 24th, 2024
- Tessera Therapeutics to Present New Data Across Preclinical Programs for its Gene Writing™ and Delivery Platforms at the American Society of Gene... - April 23rd, 2024
- GeneFab Announces Two Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024 - April 23rd, 2024
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting - April 23rd, 2024
- Excision BioTherapeutics Announces Oral Presentation Highlighting Positive Data from its HBV Program, EBT-107, at the Upcoming ASGCT 2024 Annual... - April 23rd, 2024
- Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at... - April 23rd, 2024
- CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting - April 23rd, 2024
- ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting - April 23rd, 2024
- Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs - April 23rd, 2024
- Kriya Announces Six Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024 - April 23rd, 2024
- Ring Therapeutics Announces Presentations at the 27th Annual American Society of Gene and Cell Therapy - April 23rd, 2024
- Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting - April 23rd, 2024
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy... - April 23rd, 2024
- TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting - April 23rd, 2024
- Scorpius Holdings Announces Receipt of Filing Delinquency Notification - April 23rd, 2024
- Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at... - April 23rd, 2024
- Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results - April 23rd, 2024
- Arbor Biotechnologies to Present Data Supporting Therapeutic Programs in PH1 and ALS, and the Discovery of a Novel Type V Nuclease at the American... - April 23rd, 2024
- Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice - April 23rd, 2024
- Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) - April 23rd, 2024
- Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT)... - April 23rd, 2024
- Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces... - April 19th, 2024
- Digital Utilities Ventures Completes Strategic Merger - Paving the Way for Future Growth and Innovation - April 19th, 2024
- Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant... - April 19th, 2024
- Sanara MedTech Inc. Announces $55 Million Debt Facility - April 19th, 2024
- Pharming Group announces the placement of €100 million convertible bonds due 2029 - April 19th, 2024
- Immix Biopharma on Track to Dose NXC-201 Patients in United States - April 19th, 2024
- Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. - April 19th, 2024
- Referat Fra Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00 - April 19th, 2024
- Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States - April 19th, 2024
- Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings - April 19th, 2024
- PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine - April 19th, 2024
- Codexis to Report First Quarter 2024 Financial Results on May 2 - April 19th, 2024
- ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET - April 19th, 2024
- NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s &... - April 19th, 2024
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs - April 19th, 2024
- Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted... - April 19th, 2024
- Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections - April 19th, 2024
- Addex to Present at the Swiss Biotech Day 2024 - April 19th, 2024
- Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering - April 19th, 2024
- FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer - April 19th, 2024
- Excision BioTherapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting - April 10th, 2024
- Arcutis Appoints David Topper as Chief Financial Officer - April 10th, 2024
- Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients - April 10th, 2024
- Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting - April 10th, 2024
- Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum - April 10th, 2024
- AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the... - April 10th, 2024
- Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™ - April 10th, 2024
- BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference - April 10th, 2024
- ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M - April 10th, 2024
- Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study - April 10th, 2024
- New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital - April 10th, 2024
- OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung... - April 10th, 2024
- Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR... - April 10th, 2024
- Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer - April 10th, 2024
- Epic Bio to Participate in a Fireside Chat at the Canaccord Genuity Genetic Medicine for Generalists - April 10th, 2024
- Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up - April 10th, 2024
- Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - April 10th, 2024
- Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer - April 10th, 2024
- Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs - April 10th, 2024
- PharmAla Announces Private Placement and Concurrent Debt Settlement - April 10th, 2024
Recent Comments